中国神经再生研究(英文版) ›› 2022, Vol. 17 ›› Issue (12): 2755-2760.doi: 10.4103/1673-5374.339500

• 原著:视神经损伤修复保护与再生 • 上一篇    下一篇

白细胞介素4促进小胶质细胞向视网膜缺血再灌注后的神经保护表型分化

  

  • 出版日期:2022-12-15 发布日期:2022-05-05
  • 基金资助:

Interleukin-4 promotes microglial polarization toward a neuroprotective phenotype after retinal ischemia/reperfusion injury

Di Chen1, 2, #, Cheng Peng1, 2, #, Xu-Ming Ding1, 2, Yue Wu1, 2, Chang-Juan Zeng1, 2, Li Xu1, 2, *, Wen-Yi Guo1, 2, *   

  1. 1Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China
  • Online:2022-12-15 Published:2022-05-05
  • Contact: Li Xu, PhD, x_jenny_dr@hotmail.com; Wen-Yi Guo, PhD, wyguo9h@163.com.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, No. 81970796 (to WYG), Clinical Research Program of the Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No. JYLJ201905 (to WYG), Interdisciplinary Program of Shanghai Jiao Tong University, No. YG2019QNA18 (to YW).

摘要:

小胶质细胞极化和神经炎症在视网膜变性中起着重要作用。为了解小胶质细胞极化在青光眼进展中的功能,并确定减轻视网膜神经炎症的策略。研究分为2组平行实验,一组实验为在C57BL/6小鼠中诱发了视网膜缺血再灌注损伤。另一组实验为给予视网膜缺血再灌注损伤小鼠玻璃体内注射白细胞介素4或对照溶媒。通过计数视网膜平板上的RBPMS阳性细胞来评估视网膜神经节细胞的损失,并通过定量RT-PCR、免疫荧光和免疫印迹来评估M1和M2小胶质细胞标记物的表达。结果显示,在视网膜缺血再灌注后的28d内,视网膜神经节细胞逐渐丧失,伴随着后期M2小胶质细胞的持续减少。白细胞介素4在所有时间点都在视网膜中检测不到,而玻璃体内白细胞介素4的给药极大地改善了M2小胶质细胞的标记表达,并减少了视网膜缺血再灌注后晚期视网膜神经节细胞的损失。实验表明,白细胞介素4治疗延长了视网膜缺血再灌注后M2小胶质细胞的高数量,以促进视网膜神经节细胞的生存。

https://orcid.org/0000-0002-9379-1301 (Li Xu); https://orcid.org/0000-0002-0723-6353 (Di Chen)

Abstract: Glaucoma results from irreversible loss of retinal ganglion cells (RGCs) through an unclear mechanism. Microglial polarization and neuroinflammation play an important role in retinal degeneration. Our study aimed to explore the function of microglial polarization during glaucoma progression and identify a strategy to alleviate retinal neuroinflammation. Retinal ischemia/reperfusion injury was induced in C57BL/6 mice. In a separate cohort of animals, interleukin (IL)-4 (50 ng/mL, 2 μL per injection) or vehicle was intravitreally injected after retinal ischemia/reperfusion injury. RGC loss was assessed by counting cells that were positive for the RGC marker RNA binding protein, mRNA processing factor in retinal flat mounts. The expression of classically activated (M1) and alternatively activated (M2) microglial markers were assessed by quantitative reverse transcription-polymerase chain reaction, immunofluorescence, and western blotting. The results showed that progressive RGC loss was accompanied by a continuous decrease in M2 microglia during the late phase of the 28-day period after retinal ischemia/reperfusion injury. IL-4 was undetectable in the retina at all time points, and intravitreal IL-4 administration markedly improved M2 microglial marker expression and ameliorated RGC loss in the late phase post-retinal ischemia/reperfusion injury. In summary, we observed that IL-4 treatment maintained a high number of M2 microglia after RIR and promoted RGC survival.

Key words: glaucoma, hyper-intraocular pressure, in vivo, interleukin-4, intravitreal injection, M2 microglia, neurodegeneration, neuroprotective effect, retinal ganglion cell, retinal ischemia-reperfusion